Results 181 to 190 of about 40,021 (309)

Trazodone for management of depression in Parkinson's disease: expert opinion and proposal for a treatment algorithm. [PDF]

Neurol Sci
Antonini A, Bentivoglio AR, Calandra-Buonaura G, Ceravolo R, Leta V, Pellecchia MT, Pilotto A, Nicoletti A.   +7 more
europepmc   +1 more source

Multi‐Targeting Ligands as Prospective Therapeutics for Alzheimer's Disease, a Prevalent Neurodegenerative Disorder: Mechanistic Insights, Emerging Targets and Drug Discovery Campaigns

Medicinal Research Reviews, Volume 46, Issue 4, Page 1173-1229, July 2026.
ABSTRACT Alzheimer's disease (AD) is a debilitating neurodegenerative condition characterized by progressive cognitive impairment, memory deterioration, and neuronal dysfunction. Its complex pathophysiology involves multiple interlinked processes, including amyloid‐β (Aβ) aggregation, tau hyperphosphorylation, oxidative stress, neuroinflammation ...
Amandeep Thakur, Mandeep Rana, Sakshi Vanjani, Kei‐Chi Liou, Rajeev Taliyan, Kunal Nepali, Chih‐Hao Yang   +6 more
wiley   +1 more source

The Selectivity Implications of Docking Libraries with Greater and Lesser Similarities to Bio-like Molecules. [PDF]

J Med Chem
Hall BW, Sakamoto K, Huang XP, Irwin JJ, Shoichet BK, Roth BL.   +5 more
europepmc   +1 more source

Prenatal Prescription Opioid Analgesic Exposure and Academic Performance in Third Grade Children: A Population‐Based Cohort Study

BJOG: An International Journal of Obstetrics &Gynaecology, Volume 133, Issue 8, Page 1658-1670, July 2026.
ABSTRACT Objective To evaluate the association between prenatal exposure to opioids analgesics and academic performance in third grade children. Design Population‐based cohort study using linked data from New South Wales birth records, medicine dispensing data, and national standardised test results.
Bianca Varney, Helga Zoega, Malcolm B. Gillies, Claudia Bruno, Alys Havard, Antonia Shand, Natasha Nassar, Jonathan Brett   +7 more
wiley   +1 more source

In vitro profiling of Trypanosoma cruzi inhibitors identified from High throughput Screening and application to parasite painting. [PDF]

Int J Parasitol Drugs Drug Resist
Baek KH, Lee H, Byun S, Genilloud O, Ioset JR, Shum D, No JH.   +6 more
europepmc   +1 more source

Seladelpar Improved Itch, Itch‐Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 1, Page 23-35, July 2026.
Seladelpar improved itch, itch‐related sleep disturbance and measures of fatigue in patients with primary biliary cholangitis and pruritus in the Phase 3 RESPONSE trial. ABSTRACT Background Pruritus and fatigue impose a significant burden on patient quality of life in primary biliary cholangitis (PBC).
Cynthia Levy, David E. J. Jones, Marlyn J. Mayo, Christopher L. Bowlus, Kris V. Kowdley, Gideon M. Hirschfield, Jie Liu, Caroline Burk, Susheela Carroll, Daria B. Crittenden, Andreas E. Kremer   +10 more
wiley   +1 more source

The Spectrum of Iatrogenic Valvular Heart Disease. [PDF]

JACC Case Rep
Benfari G, Tribouilloy C, Enriquez-Sarano M.   +2 more
europepmc   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, Volume 183, Issue 14, Page 3970-3991, July 2026.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Glucagon-like Peptide-1 and Dual GIP/GLP-1 Receptor Agonists in Brain: Exploring the Expanding Role and Safety in Neuropsychiatry. [PDF]

Int J Mol Sci
Tudosie AC, Marin LM, Popa SG, Golli AL.
europepmc   +1 more source

The Australia story: Current status and future challenges for the clinical applications of psychedelics

British Journal of Pharmacology, Volume 183, Issue 14, Page 4048-4057, July 2026.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt, Peter Hunt, Anne Katrin Schlag, Paul Fitzgerald   +3 more
wiley   +1 more source